Howard Hughes Medical Institute

Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round

Retrieved on: 
Thursday, October 20, 2022
Health, Trust, Lists of diseases, ESG, RMB, Biotechnology, Technology, R, University, VC, HHMI, Guangzhou, Industry, CDMO, UNPRI, Howard Hughes Medical Institute, Chicago (franchise), USD, CRO, Fine chemical

HONG KONG, Oct 20, 2022 - (ACN Newswire) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital.

Key Points: 
  • HONG KONG, Oct 20, 2022 - (ACN Newswire) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital.
  • The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine.
  • VectorBuilder has become a pioneer in the entire gene delivery industry chain by empowering basic scientific research and accelerating the clinical application of gene drugs.
  • Jeff Wang, Managing Director of Legend Capital, said: "VectorBuilder is the world's leading gene delivery company, providing full-chain solutions from basic scientific research to clinical application of gene delivery.

Kindbody's Nationwide Expansion Continues with Opening of Houston Clinic

Retrieved on: 
Tuesday, October 11, 2022
National Institutes of Health, Adoption, Reproductive health, Emory University, Walter Reed National Military Medical Center, Parent, Education, Gynaecology, Patient, Restaurant, NIH, Research, Program, Corporation, GV (company), University, MedStar Georgetown University Hospital, National, Society, CEO, IVF, Genetic testing, Fertility, Howard Hughes Medical Institute, Infertility, Uterine fibroid, Heart, Obstetrics, Fertility preservation, Medicine

NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody, a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX. Kindbody Houston was built to meet the growing demand for comprehensive fertility and family-building benefits by employers in the area, which has experienced record job growth with its thriving local economy. Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology. Dr. Parikh is currently accepting patients. The opening marks the company's second location in Texas which is also home to Kindbody Austin. A third Texas location will launch in Dallas later this year.

Key Points: 
  • NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Kindbody , a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care, today announced the opening of a state-of-the-art clinic and IVF lab in Houston, TX.
  • Open to the entire Houston community, Kindbody Houston is led by Dr. Toral Parikh, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology.
  • The opening marks the company's second location in Texas which is also home to Kindbody Austin.
  • "We're excited to bring Kindbody's mission of accessible, high-quality fertility care to Houston employers and the entire community," said Annbeth Eschbach, CEO, Corporate of Kindbody.

Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer

Retrieved on: 
Monday, October 10, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, CA, Disease, Therapy, Growth, Harvey Fellows, Yale University, Cell, Patient, Biotechnology, List of life sciences, Research, NIH, Publication, PNAS, Carleton College, Company, Cowen, Industry, National, NEA, CEO, MIT, Molecular biology, Howard Hughes Medical Institute, TYK2, Massachusetts Institute of Technology, Management, Pharmaceutical industry, Nature, Biology

Sudo Biosciences (Sudo), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer.

Key Points: 
  • Sudo Biosciences (Sudo), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer.
  • Imran brings to Sudo extensive experience in corporate strategy and business development, as well as his track record of financing and building biotech companies.
  • He is exactly the type of leader Sudo needs as we advance into our next phase of growth, said Scott Byrd, CEO, Sudo Biosciences.
  • I am excited to join Sudo Biosciences and apply my experience to help patients with auto-immune diseases, said Imran Babar, Ph.D., chief business officer of Sudo Biosciences.

Norovirus Link to Crohn's Disease May Point to New Therapies

Retrieved on: 
Wednesday, October 5, 2022
Diamond, National Institutes of Health, Biochemistry, Howard Hughes Medical Institute, The Kenneth Rainin Foundation, Disease, Virus, Infection, Crohn's disease, Pharmacology, Crohn's & Colitis Foundation, API5, Geisinger Health System, NYU, Diarrhea, New York University Grossman School of Medicine, Patient, Rockefeller University, Research, MPH, Nature, Harvard Medical School, NYU Langone Health, Cadwell, Mouse, Immune system, Vomiting, Mutation, PureTech Health, Doctor of Philosophy, Department, National, Bacteria, Injection, Pacific Biosciences, Apoptosis, Human, Vaccine, Pharmaceutical industry, Pfizer, Takeda, Genentech, MD, Norovirus, Microbiology

Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.

Key Points: 
  • Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.
  • One clue emerged when past studies found that a certain genetic change (mutation) is present in most patients with the condition.
  • This protein adds an extra layer of protection against immune damage, so even those with the mutation can have a healthy gut.
  • However, the researchers also found that norovirus infection blocks T cell secretion of API5 in mice bred to have a rodent form of Crohn's disease, killing gut-lining cells in the process.

EQS-News: Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Retrieved on: 
Tuesday, October 4, 2022
Duke University School of Medicine, Howard Hughes Medical Institute, Tick-Borne Disease Alliance, Cancer, Physician, Obesity, Nasdaq, Research, School of Life Sciences (University of Dundee), Privacy, Prevalence, Blood, FDA, Infection, COVID-19, Borrelia burgdorferi, Method, University of Washington, Patient, Hypertension, University, Pharmacology, Vaccine, Pharmaceutical industry, Lyme disease, Quidel Corporation

It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).

Key Points: 
  • It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).
  • The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance.
  • Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine.
  • Quidel is the diagnostic health care manufacturer behind the industrys most rapid and reliable in-office test for Lyme disease, Sofia 2 Lyme FIA.

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Retrieved on: 
Tuesday, October 4, 2022
Health, Infectious Diseases, Hospitals, Managed Care, General Health, Pharmaceutical, Biotechnology, Duke University School of Medicine, Howard Hughes Medical Institute, Tick-Borne Disease Alliance, Cancer, Physician, Obesity, Nasdaq, Research, School of Life Sciences (University of Dundee), Privacy, Prevalence, Blood, FDA, COVID-19, Infection, Borrelia burgdorferi, Method, University of Washington, Patient, Hypertension, University, Pharmacology, Vaccine, Pharmaceutical industry, Lyme disease, Quidel Corporation

It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).

Key Points: 
  • It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugsnovel inhibitorscan selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease).
  • The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance.
  • Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine.
  • Quidel is the diagnostic health care manufacturer behind the industrys most rapid and reliable in-office test for Lyme disease, Sofia 2 Lyme FIA.

Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response

Retrieved on: 
Tuesday, October 4, 2022
Epithelium, Darrell Irvin, Injection, Cancer, Vaccine, Muscle, Koch Institute for Integrative Cancer Research, Immunoglobulin A, Immunization, Serum, KRAS, Immunity, Doctor of Philosophy, Vaccination, Immunotherapy, Nose, Research, Severe acute respiratory syndrome coronavirus 2, Immunology, Biomedicine, Compliance, Engineering, Immunoglobulin G, Koch Institute, RBD, Massachusetts Institute of Technology, Elicio Berriz, Protein, Time-invariant system, FDA, Antibody, Mouse, COVID-19, Nasal mucosa, Infection, Immune system, HIV, Biomedical engineering, Howard Hughes Medical Institute, Lymph, Therapy, Science Translational Medicine, Â, AMP, MIT, Forward-looking statement, TCR, Risk, Laboratory, Amplifier, GLOBE, Pharmaceutical industry, Amphiphile, Nasal administration

BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology (MIT), demonstrating Elicio’s Amphiphile (AMP) platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization. Immunization through airway surfaces has proven challenging due to poor vaccine uptake across these linings. The data presented here represents a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases. The data was published in Science Translational Medicine and can be accessed here.

Key Points: 
  • The data was published in Science Translational Medicine and can be accessed here .
  • Delivery of vaccine components across mucosal barriers has been a major challenge for mucosal vaccine development.
  • This data demonstrates that AMP-modification can improve vaccine uptake across the nasal mucosa via interactions with albumin and the neonatal Fc receptor known as the mucosal gateway.
  • The findings are encouraging for the translational potential of this approach to induce antibodies in a variety of mucosal sites after intranasal immunization.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022
Health, Faculty, Volunteering, Lone Star Distinguished Service Medal, Time, Circle, Lists of diseases, Woman, Love, Jan, Hospital, Neurodegeneration, Texas Children's Hospital, Hope, Autism, Life, Duncan, Tic disorder, Patient, Epilepsy, Baylor University, Bluebird, Physician, Rett syndrome, Howard Hughes Medical Institute, Neurology, Research, Neurological disorder, Multimedia, View, Alzheimer's disease, Depression, Baylor College of Medicine, Pharmaceutical industry

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Celsius Therapeutics Names Scientific Advisers

Retrieved on: 
Thursday, September 22, 2022
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Computer science, Autoimmunity, Netherlands Cancer Institute, Leonard M. Miller School of Medicine, Doctor of Philosophy, Autoimmune disease, Department, FRS, Weizmann Institute of Science, Third Rock Ventures, ECCO, Twitter, Machine learning, Immunology, Inflammatory bowel disease, University of California, Berkeley, European, Nutrition, LinkedIn, Terra Venture Partners, Computational biology, Yale School of Medicine, Therapy, Patient, Clinical trial, Cleveland Clinic, Cancer, CEO, Transcriptome, Ulcerative colitis, Biology, Associate professor, Howard Hughes Medical Institute, Harvard Medical School, B cell, RNA, Research, Biotechnology, IBD, University, Health informatics, Electrical engineering, Pharmaceutical industry, Vaccine, Celsius, Microbiology, Medicine

Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.

Key Points: 
  • Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.
  • As Celsius prepares to advance our first programs into the clinic, we are entering a transitional point in our evolution, said Tariq Kassum, M.D., President and CEO of Celsius.
  • Director, Crohns and Colitis Center, Professor of Medicine, and Professor of Microbiology and Immunology, University of Miami Miller School of Medicine.
  • Celsius Therapeutics is a biotechnology company developing novel precision medicines in autoimmune disease and cancer by harnessing the power of single cell RNA sequencing and human biology at scale.

ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

Retrieved on: 
Tuesday, September 20, 2022
ICI, Molecular biology, Cytokine, Interferon, Autoimmunity, FDA, Neoplasm, Company, Immunity, Therapy, University of Texas Southwestern Medical Center, Cancer Prevention and Research Institute of Texas, Clinical trial, Cancer, CEO, Hyperkinesia, Radiation, Degenerative disease, Howard Hughes Medical Institute, Cancer prevention, GLOBE, University, Pain scale, Research institute, Pharmaceutical industry

STING agonist in combination with immune checkpoint inhibitors (ICI) and other therapies such as radiotherapy can mobilize and coordinate a patients immune system against cancer.

Key Points: 
  • STING agonist in combination with immune checkpoint inhibitors (ICI) and other therapies such as radiotherapy can mobilize and coordinate a patients immune system against cancer.
  • We are delighted and honored to receive this grant from CPRIT which will support the continued clinical development of IMSA101.
  • ImmuneSensor is a world leader in the cGAS-STING pathway, based on groundbreaking discoveries by Dr. Zhijian James Chen at the University of Texas Southwestern Medical Center (UTSW).
  • ImmuneSensor Therapeutics Inc. (ImmuneSensor) is a private clinical stage biotechnology company dedicated to harnessing innate immunity to treat cancer and autoimmune diseases.